OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free
Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.
Vincent Jiangthree-minute read
Paper exams, from the CEO who put AI in the chart
Daniel Nadler, founder and chief executive of the medical-literature search engine OpenEvidence~$6B — OpenEvidence, private, latest valuation ~$6B, told Semafor's Silicon Valley & The World event on November 16 that medical students should "learn the hard way, do paper exams" even if they also use AI 1. "The risk of cognitive offloading is really, really acute," he said, cognitive offloading being the handing of mental work to a machine, and sharpest for students who have studied with AI from the start 1. Semafor put his company's value at $15 billion 1, a mark set by a $250 million September round, earned on advertising revenue, with verified doctors paying nothing 2.
OpenEvidence's valuation climbed from $1 billion to $15 billion in 19 months
Valuation rose 15-fold in 19 months while the product stayed free to doctors
Data
| Post-money valuation | |
|---|---|
| Feb '25 | $1B |
| Jul '25 | $3.5B |
| Oct '25 | $6B |
| Jan '26 | $12B |
| Sep '26 | $15B |
Two small studies back the warning
The warning has numbers behind it. A 2025 Lancet study found skilled doctors spotted fewer precancerous growths without AI after months of using it, 22.4% unaided against 28.4% before 1. An MIT Media Lab study of 54 people found the weakest brain connectivity among those writing essays with ChatGPT 1. Both were small 1.
The bite is the deployment: since October 20, OpenEvidence has sat inside NYU Langone Health's Epic medical-record system, reaching 12.4 million outpatient visits a year and more than 6,000 physicians, among them the 2,000-plus residents and fellows training at NYU's two medical schools 3. The cohort Nadler wants on paper already has his tool in the chart.
Free answers from three giants
The same week stacked free supply against that valuation. Anthropic$350B — Anthropic, private, latest valuation $350B, maker of Claude, agreed in September to supply OpenEvidence free to clinicians in about 100 countries, with financial terms undisclosed 4.
On November 15, Apple+0.08% — Apple, up 0.08 percent today put OpenEvidence in front of up to 200,000 U.S. consumers in a health study, no commercial terms disclosed 5, a launch The Inference covered on November 16. A day later, OpenAI$1.18T — OpenAI, private, latest valuation $1.18T loaded more than 20 health plugins into ChatGPT for Healthcare, where ChatGPT for Clinicians is free for eligible U.S. doctors, and priced its GPT-6 Luna admin agent at 8.5 cents a task, 98% below the frontier model 67.
Licensable content is what free answers cannot copy
The defense is scale and licenses. U.S. clinicians consulted OpenEvidence 42 million times in August alone 4, and the company holds content agreements with NEJM, JAMA, Nature, NCCN and Cochrane 8. Licensed clinical content can hold a price where general answers cannot; advertising aimed at doctor screens is what free supply cuts. Before paying the September mark, investors should want the Apple and health-system economics disclosed, and a view on what a pharma ad is worth beside a free ChatGPT. Nadler's own warning prices the risk: the scarce asset is not the answer but the doctor who can check it.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.






Reader comments
0 comments